Tirzepatide Albuminuria Kidney SURPASS Pooled Analysis
A pooled SURPASS 1–5 post hoc analysis found tirzepatide reduced UACR by 19–26% versus comparators, including in patients with early CKD.
A pooled SURPASS 1–5 post hoc analysis found tirzepatide reduced UACR by 19–26% versus comparators, including in patients with early CKD.